RSS Feeds
New Onset of Myelofibrosis in Association with Pulmonary Arterial Hypertension
- Uday Popat, MD;
- Adaani Frost, MD;
- Enli Liu, MD;
- Romelia May;
- Remzi Bag, MD;
- Vishnu Reddy, MD; and
- Josef T. Prchal, MD
- From Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, and University of Alabama at Birmingham, Birmingham, AL 35233.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Marrow fibrosis (myelofibrosis) occurs in patients with idiopathic myelofibrosis and other myeloproliferative disorders, which are characterized by a clonal hematopoiesis (1), and in patients with lupus erythematosus and cancer involving marrow. However, to our knowledge, myelofibrosis has not been previously reported in patients presenting with pulmonary arterial hypertension. The observation of severe myelofibrosis in a patient with this disorder prompted us to systematically evaluate patients …
